{"title":"铁治疗对慢性心力衰竭和缺铁性贫血的影响:系统回顾和荟萃分析。","authors":"Yusra Pintaningrum, Ni Putu Yunandari","doi":"10.1186/s43044-024-00545-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Heart failure complicated with iron deficiency is associated with impaired functional capacity, poor quality of life, increased hospitalization, and mortality. This systematic review and meta-analysis were conducted to assess the effect of oral and intravenous iron therapy on functional capacity, hospitalization risk, and mortality risk in patients with chronic heart failure and iron-deficiency anemia.</p><p><strong>Methods: </strong>Search for published scientific articles using the PRISMA (Preferred Reporting, Items for Systematic Reviews and Meta-Analysis) method conducted on Cochrane Library, PubMed Central, and Medline databases published in the last 20 years. Further systematic review and meta-analysis using RevMan version 5.4 were performed based on the included published scientific articles.</p><p><strong>Results: </strong>Based on the meta-analysis of included studies, the analytical results of intravenous iron therapy in patient with chronic heart failure and iron-deficiency anemia showed there is 30.82 (MD = 30.82: 95% CI 18.23-43.40) meter change in patient 6MWT, there is likelihood of 0.55 times (55%) (RR = 0.45: 95% CI 0.30-0.68) lower risk of hospitalization and lower risk of mortality (RR = 0.18: 95% CI 0.04-0.78), because heart failure worsening both with statistically significant overall effect compared with placebo.</p><p><strong>Conclusions: </strong>There is statistically significant effect of intravenous iron therapy to improve patient functional capacity and reduce likelihood of hospitalization risk of 0.55 times (55%) in patient with chronic heart failure and iron-deficiency anemia.</p>","PeriodicalId":74993,"journal":{"name":"The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology","volume":"76 1","pages":"116"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11364828/pdf/","citationCount":"0","resultStr":"{\"title\":\"Iron therapy effect on chronic heart failure and iron-deficiency anemia: a systematic review and meta-analysis.\",\"authors\":\"Yusra Pintaningrum, Ni Putu Yunandari\",\"doi\":\"10.1186/s43044-024-00545-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Heart failure complicated with iron deficiency is associated with impaired functional capacity, poor quality of life, increased hospitalization, and mortality. This systematic review and meta-analysis were conducted to assess the effect of oral and intravenous iron therapy on functional capacity, hospitalization risk, and mortality risk in patients with chronic heart failure and iron-deficiency anemia.</p><p><strong>Methods: </strong>Search for published scientific articles using the PRISMA (Preferred Reporting, Items for Systematic Reviews and Meta-Analysis) method conducted on Cochrane Library, PubMed Central, and Medline databases published in the last 20 years. Further systematic review and meta-analysis using RevMan version 5.4 were performed based on the included published scientific articles.</p><p><strong>Results: </strong>Based on the meta-analysis of included studies, the analytical results of intravenous iron therapy in patient with chronic heart failure and iron-deficiency anemia showed there is 30.82 (MD = 30.82: 95% CI 18.23-43.40) meter change in patient 6MWT, there is likelihood of 0.55 times (55%) (RR = 0.45: 95% CI 0.30-0.68) lower risk of hospitalization and lower risk of mortality (RR = 0.18: 95% CI 0.04-0.78), because heart failure worsening both with statistically significant overall effect compared with placebo.</p><p><strong>Conclusions: </strong>There is statistically significant effect of intravenous iron therapy to improve patient functional capacity and reduce likelihood of hospitalization risk of 0.55 times (55%) in patient with chronic heart failure and iron-deficiency anemia.</p>\",\"PeriodicalId\":74993,\"journal\":{\"name\":\"The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology\",\"volume\":\"76 1\",\"pages\":\"116\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11364828/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s43044-024-00545-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43044-024-00545-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:心力衰竭并发缺铁与功能受损、生活质量差、住院率和死亡率增加有关。本系统综述和荟萃分析旨在评估口服和静脉铁剂治疗对慢性心力衰竭合并缺铁性贫血患者的功能能力、住院风险和死亡风险的影响:采用 PRISMA(系统综述和荟萃分析的首选报告项目)方法,在 Cochrane 图书馆、PubMed Central 和 Medline 数据库中搜索过去 20 年发表的科学文章。根据纳入的已发表科学文章,使用 RevMan 5.4 版进行了进一步的系统综述和荟萃分析:根据对纳入研究的荟萃分析,对慢性心力衰竭合并缺铁性贫血患者进行静脉铁剂治疗的分析结果显示,患者6MWT的变化为30.82(MD = 30.82:95% CI 18.23-43.40)米,有可能是6MWT的0.55倍(55%)(RR = 0.45:95% CI 0.30-0.68),住院风险和死亡风险较低(RR = 0.18:95% CI 0.04-0.78),因为与安慰剂相比,心衰恶化的总体效果均有统计学意义:结论:对于慢性心力衰竭合并缺铁性贫血的患者来说,静脉铁剂治疗对改善患者功能和降低住院风险有明显的统计学作用,其效果是安慰剂的0.55倍(55%)。
Iron therapy effect on chronic heart failure and iron-deficiency anemia: a systematic review and meta-analysis.
Background: Heart failure complicated with iron deficiency is associated with impaired functional capacity, poor quality of life, increased hospitalization, and mortality. This systematic review and meta-analysis were conducted to assess the effect of oral and intravenous iron therapy on functional capacity, hospitalization risk, and mortality risk in patients with chronic heart failure and iron-deficiency anemia.
Methods: Search for published scientific articles using the PRISMA (Preferred Reporting, Items for Systematic Reviews and Meta-Analysis) method conducted on Cochrane Library, PubMed Central, and Medline databases published in the last 20 years. Further systematic review and meta-analysis using RevMan version 5.4 were performed based on the included published scientific articles.
Results: Based on the meta-analysis of included studies, the analytical results of intravenous iron therapy in patient with chronic heart failure and iron-deficiency anemia showed there is 30.82 (MD = 30.82: 95% CI 18.23-43.40) meter change in patient 6MWT, there is likelihood of 0.55 times (55%) (RR = 0.45: 95% CI 0.30-0.68) lower risk of hospitalization and lower risk of mortality (RR = 0.18: 95% CI 0.04-0.78), because heart failure worsening both with statistically significant overall effect compared with placebo.
Conclusions: There is statistically significant effect of intravenous iron therapy to improve patient functional capacity and reduce likelihood of hospitalization risk of 0.55 times (55%) in patient with chronic heart failure and iron-deficiency anemia.